News
Watch
Conferences
Publications
CME/CE
Resources
Subscribe
About
Partnerships

Jane E. Salmon, MD

Articles by Jane E. Salmon, MD

Jane E. Salmon, MD, on the IMPACT trial of certolizumab pegol for adverse pregnancy outcomes in APS

October 13th 2026

On September 9, 2026, certolizumab pegol received FDA Breakthrough Therapy Designation for APS pregnancy; Jane E. Salmon, MD, reviews the IMPACT trial results behind it.

Jane E. Salmon, MD

Articles by Jane E. Salmon, MD

Jane E. Salmon, MD, on the IMPACT trial of certolizumab pegol for adverse pregnancy outcomes in APS

Latest Updated Articles